Commonly, type II involves FGFR2-AFF3 and FGFR2-CASP7 gene fusions abnormally activating FGFR2 in breast cancer while type I concerns CNTRL–FGFR1 and ETV6–FGFR3 gene fusions leading to acute myeloid and lymphoid leukaemia patients [41]. This evidence concerns the gene FGFR2 and breast cancer.